Section Arrow
ACRV.NASDAQ
- Acrivon Therapeutics
Quotes are at least 15-min delayed:2024/04/29 15:28 EDT
Last
 9.96
+1.5 (+17.73%)
Day High 
10.16 
Prev. Close
8.46 
1-M High
11.9 
Volume 
187.87K 
Bid
9.87
Ask
9.96
Day Low
8.1829 
Open
8.22 
1-M Low
5.7 
Market Cap 
261.18M 
Currency USD 
P/E -- 
%Yield
10-SMA 9.51 
20-SMA 8.7 
50-SMA 6.58 
52-W High 14.3 
52-W Low 3.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.74/-3.44
Enterprise Value
264.94M
Balance Sheet
Book Value Per Share
3.93
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.9941+0.134+15.58%-- 
JAGXJaguar Health0.2026+0.0226+12.56%-- 
IBRXImmunityBio8.75+1.4+19.05%-- 
GERNGeron Corp4.185+0.395+10.42%-- 
XFORX4 Pharmaceuticals1.15-0.015-1.29%-- 
Quotes are at least 15-min delayed:2024/04/29 15:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.